Impact of Bile Acids on the Growth of Human Cholangiocarcinoma Via FXR

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2011 Oct 13

PMID 21988803

Citations 38

Authors

Jiaqi Dai

Hongxia Wang

Yihui Shi

Ying Dong

Yinxin Zhang

Jian Wang

Affiliations

Soon will be listed here.

Abstract

Background: The objective of the study was to investigate the effect of different types of bile acids on proliferation of cholangiocarcinoma and the potential molecular mechanisms.

Methods: PCR assay and Western blot were performed to detect the expression of farnesoid × receptor (FXR) in mRNA and protein level. Immunohistochemical analysis was carried out to monitor the expression of FXR in cholangiocarcinoma tissues from 26 patients and 10 normal controls. The effects on in vivo tumor growth were also studied in nude mouse model.

Results: Free bile acids induced an increased expression of FXR; on the contrary, the conjugated bile acids decreased the expression of FXR. The FXR effect has been illustrated with the use of the FXR agonist GW4064 and the FXR antagonist GS. More specifically, when the use of free bile acids combined with FXR agonist GW4064, the tumor cell inhibitory effect was even more pronounced. But adding FXR antagonist GS into the treatment attenuated the tumor inhibitory effect caused by free bile acids. Combined treatment of GS and CDCA could reverse the regulating effect of CDCA on the expression of FXR. Administration of CDCA and GW 4064 resulted in a significant inhibition of tumor growth. The inhibitory effect in combination group (CDCA plus GW 4064) was even more pronounced. Again, the conjugated bile acid-GDCA promoted the growth of tumor. We also found that FXR agonist GW4064 effectively blocked the stimulatory effect of GDCA on tumor growth. And the characteristic and difference of FXR expressions were in agreement with previous experimental results in mouse cholangiocarcinoma tissues. There was also significant difference in FXR expression between normal and tumor tissues from patients with cholangiocarcinoma.

Conclusions: The imbalance of ratio of free and conjugated bile acids may play an important role in tumorigenesis of cholangiocarcinoma. FXR, a member of the nuclear receptor superfamily, may mediate the effects induced by the bile acids.

Citing Articles

Carcinogenic and anticancer activities of microbiota-derived secondary bile acids.

Kouhzad M, Gotz F, Navidifar T, Taki E, Ghamari M, Mohammadzadeh R Front Oncol. 2025; 15:1514872.

PMID: 39944822 PMC: 11813773. DOI: 10.3389/fonc.2025.1514872.

Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.

Wu N, Bayatpour S, Hylemon P, Aseem S, Aseem S, Brindley P Am J Pathol. 2024; 195(3):397-408.

PMID: 39730075 PMC: 11841492. DOI: 10.1016/j.ajpath.2024.11.004.

Identification of molecular subtypes based on bile acid metabolism in cholangiocarcinoma.

Deng M, Liu J, Zhang L, Lou Y, Qiu Y BMC Cancer. 2024; 24(1):1313.

PMID: 39455933 PMC: 11515294. DOI: 10.1186/s12885-024-13081-0.

Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study.

Daniel N, Farinella R, Chatziioannou A, Jenab M, Mayen A, Rizzato C Sci Rep. 2024; 14(1):25144.

PMID: 39448785 PMC: 11502931. DOI: 10.1038/s41598-024-77431-5.

Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma.

Jackson L, Tomlinson J, Alva-Ruiz R, Gregory L, Byeon S, Abdelrahman A JHEP Rep. 2024; 6(6):101068.

PMID: 38882601 PMC: 11179355. DOI: 10.1016/j.jhepr.2024.101068.

References

Journe F, Laurent G, Chaboteaux C, Nonclercq D, Durbecq V, Larsimont D . Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat. 2007; 107(1):49-61. DOI: 10.1007/s10549-007-9535-6. View

Bernstein H, Bernstein C, Payne C, Dvorak K . Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol. 2009; 15(27):3329-40. PMC: 2712893. DOI: 10.3748/wjg.15.3329. View

Wang J, Shi Y, Yi J, Ye S, Wang L, Xu Y . Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. J Dig Dis. 2008; 9(4):228-37. DOI: 10.1111/j.1751-2980.2008.00352.x. View

Zhang X, Ye H, Zeng C, He B, Zhang H, Chen Y . Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol. 2010; 3:46. PMC: 3002909. DOI: 10.1186/1756-8722-3-46. View

Yang F, Huang X, Yi T, Yen Y, Moore D, Huang W . Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007; 67(3):863-7. DOI: 10.1158/0008-5472.CAN-06-1078. View

Budhu A, Ji J, Wang X . The clinical potential of microRNAs. J Hematol Oncol. 2010; 3:37. PMC: 2958878. DOI: 10.1186/1756-8722-3-37. View

Wang J, Dai J, Zhang C . [Effects of bile acids on expression of interleukin-6 and cell viability in QBC939 cell line]. Zhonghua Wai Ke Za Zhi. 2010; 48(12):919-23. View

Kim I, Ahn S, Inagaki T, Choi M, Ito S, Guo G . Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007; 48(12):2664-72. DOI: 10.1194/jlr.M700330-JLR200. View

Li Y, Swales K, Thomas G, Warner T, Bishop-Bailey D . Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007; 27(12):2606-11. DOI: 10.1161/ATVBAHA.107.152694. View

10.

Muhlbauer M, Allard B, Bosserhoff A, Kiessling S, Herfarth H, Rogler G . Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2004; 286(6):G1000-8. DOI: 10.1152/ajpgi.00338.2003. View

11.

Wolf G . Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. Nutr Rev. 2008; 66(1):55-9. DOI: 10.1111/j.1753-4887.2007.00006.x. View

12.

Javle M, Hsueh C . Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol. 2010; 3:11. PMC: 2856525. DOI: 10.1186/1756-8722-3-11. View

13.

Wang Y, Chen W, Wang M, Yu D, Forman B, Huang W . Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008; 48(5):1632-43. PMC: 3056574. DOI: 10.1002/hep.22519. View

14.

Trauner M . The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?. Hepatology. 2004; 40(1):260-3. DOI: 10.1002/hep.20294. View

15.

Zhang Y, Lee F, Barrera G, Lee H, Vales C, Gonzalez F . Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006; 103(4):1006-11. PMC: 1347977. DOI: 10.1073/pnas.0506982103. View

16.

Modica S, Murzilli S, Salvatore L, Schmidt D, Moschetta A . Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 2008; 68(23):9589-94. DOI: 10.1158/0008-5472.CAN-08-1791. View

17.

Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T . Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006; 66(21):10517-24. DOI: 10.1158/0008-5472.CAN-06-2130. View

18.

Swales K, Korbonits M, Carpenter R, Walsh D, Warner T, Bishop-Bailey D . The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 2006; 66(20):10120-6. DOI: 10.1158/0008-5472.CAN-06-2399. View

19.

Huang L, Zhao A, Lew J, Zhang T, Hrywna Y, Thompson J . Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem. 2003; 278(51):51085-90. DOI: 10.1074/jbc.M308321200. View

20.

Dvorak K, Chavarria M, Payne C, Ramsey L, Crowley-Weber C, Dvorakova B . Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res. 2007; 13(18 Pt 1):5305-13. DOI: 10.1158/1078-0432.CCR-07-0483. View